Abstract: A laminate includes a first glass article having a first thickness, a first annealing point (TA1), and a first softening point (TS1), a second glass article having a second thickness, a second annealing point (TA2), and a second softening point (TS2), and an interlayer disposed between the first glass article and the second glass article. The first thickness is greater than the second thickness, the second annealing point (TA2) is less than or equal to the first annealing point (TA1), and the second softening point (TS2) is greater than the first softening point (TS1).

Abstract: A control panel for an appliance defines a display direction and includes a printed circuit board defining a first surface, a second surface opposite the first surface along the display direction, and a through hole passing through the printed circuit board from the first surface to the second surface. A console cover is mounted to the first surface of the printed circuit board, a standoff feature is positioned between the console cover and the printed circuit board to create a localized gap between the console cover and the printed circuit board, a retention feature engages the second surface to retain the printed circuit board against the console cover, and an electronic component mounted to the printed circuit board and having an electrical contact that extends through the through hole where it forms a connection joint that is positioned within the localized gap.

Abstract: A dishwasher appliance is provided. The dishwasher appliance may include a cabinet, a door pivotably mounted to the cabinet, and a control panel located on a panel of the door. The control panel may include a printed circuit board, a light source, and a control cover. The printed circuit board may define a top surface and a bottom surface. The light source may be mounted to the bottom surface of the printed circuit board for selectively generating light. The control cover may be mounted to the top surface and may extend parallel to the top surface. The control cover may define a light channel. The control cover may include a reflective surface extending towards the light source from the control surface. The reflective surface may be angled to direct light selectively generated from the light source towards the light channel.

Abstract: A door for an appliance includes a control panel mounted on the door and defining an illumination direction. The control panel includes a printed circuit board defining a top surface, a light source mounted to the top surface of the printed circuit board, a control cover mounted to the top surface of the printed circuit board over the light source and defining a light directing channel extending from a bottom surface of the control cover to a top surface of the control cover, and wherein the control cover further defines a reflective surface for redirecting the light generated by the light source toward the top surface of the control cover, and an overlay panel mounted on the top surface of the control cover, the overlay panel comprising one or more diffused indicator zones.

Abstract: Solid forms comprising pyrazolylaminoquinazoline, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.

Abstract: Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-fe][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert-Butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-&][1,3]benzo-thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers.

Abstract: Solid forms comprising pyrazolylaminoquinazoline, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.

Abstract: Provided herein are hydrobromide salts of a pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.

Abstract: Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-fe][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert-Butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-&][1,3]benzo-thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers.

Abstract: Provided herein are hydrobromide salts of a pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.